{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "DELSTRIGO is a prescription medication combining doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg) in an oral tablet. It's used to treat HIV-1 infection in adults and children weighing at least 35 kg, working by inhibiting the virus's ability to replicate. Marketed by Merck Sharp & Dohme LLC since 2018. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Doravirine, lamivudine, and tenofovir disoproxil fumarate \u2014 ANDA 210807 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210807", "mediaType": "text/html", "title": "Doravirine, lamivudine, and tenofovir disoproxil fumarate"}], "identifier": "ANDA210807", "issued": "2016-09-16", "keyword": ["drug", "fda", "medications", "prescription-drugs", "public-health"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Doravirine, lamivudine, and tenofovir disoproxil fumarate"}